Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 33881-33890 Newer>

The Motley Fool January 8, 2009 Christopher Barker	Too Much of a Good Thing for Miners? The recent enormous rally among shares of virtually all metal miners, from BHP Billiton to Yamana Gold -- may be too much, too soon.
The Motley Fool January 7, 2009 Tim Beyers	Apple Blew It Apple's hardware and software engineers worked hard to create new innovations. Too bad they didn't spend more time on products that will make serious money.
The Motley Fool January 7, 2009 Alyce Lomax	Tough Times, Great Opportunities As disappointed as you may be about what's transpired, and as concerned as you may be about the current state of the economy and what might happen going forward, you should still fervently believe in long-term, buy-and-hold investing.
The Motley Fool January 7, 2009 Toby Shute	Here Comes the Oil-Services Slump With crude oil down to the low $40s, even the most sought-after rigs may see their going rates ratcheted down before long.
The Motley Fool January 7, 2009 Dan Caplinger	The Bear's Not Over Yet Despite the more positive attitude investors adopted in the New Year, don't expect stocks to go straight up from here on out.
The Motley Fool January 7, 2009 Toby Shute	Mosaic, Mo' Problems The fertilizer pipeline is stuffed today, but in a few months' time, it could be too late to get fertilizer to everyone desiring it.
The Motley Fool January 7, 2009 Brian Orelli	A One-Hit Wonder Goes for No. 2 Onyx Pharmaceuticals announces its second license in the last few months.
The Motley Fool January 7, 2009 Rich Smith	Cisco Sounds a Worrisome Note Cisco introduces a "Wireless Home Audio system" to its Linksys customer base, but it may the right product at the wrong time.
The Motley Fool January 7, 2009 David Lee Smith	Dow Chemical Goes A-Courtin' Dow Chemical will travel the legal trail to salvage what it can from a cancelled joint venture with a state-owned Kuwaiti company.
The Motley Fool January 7, 2009 Brian Orelli	A Free Call Option on a Drug Orphan-drug specialist BioMarin announces that it has licensed Riquent, La Jolla Pharmaceutical's phase 3 lupus nephritis treatment.
<Older 33881-33890 Newer> Return to current articles.